RUNX1 and acute myeloid leukemia: In fact, adults treated for RUNX1–RUNX1T1-positive AML can exhibit persistence of the fusion in the blood for years in the absence of disease relapse (Kusec et al., 1994; Miyamoto et al., 1996).